" class="no-js "lang="en-US"> Florian Bieber - Medtech Alert
Saturday, September 13, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Florian Bieber

Florian Bieber

About Florian Bieber

Florian joined Novartis in 2014 as Clinical Development Head in Established Medicines. In 2016 he was promoted to Global Head of Clinical Development. Since then he also became responsible for Biostatistics and Pharmacometrics and since 2016 for Oncology Clinical Development. Prior to joining Novartis Florian was at CMO at Merck Serono, held leadership roles for Clinical Development and PV at Novartis Consumer Health and Human Genome Sciences Europe. He started his carreer at Bayer.

Related Story

Central Nervous System

 Applications for Proposed First-of-a-kind Multiple Sclerosis Biosimilar Natalizumab Accepted by US FDA and EMA | Pharmtech Focus

Applications for Proposed First-of-a-kind Multiple Sclerosis Biosimilar Natalizumab Accepted by US FDA and EMA

July 26 2022

Sandoz, a global leader in generic and biosimilar medicines, announced today that the US Food […]